JP2013522311A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522311A5
JP2013522311A5 JP2013500162A JP2013500162A JP2013522311A5 JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5 JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013500162 A JP2013500162 A JP 2013500162A JP 2013522311 A5 JP2013522311 A5 JP 2013522311A5
Authority
JP
Japan
Prior art keywords
phe
lys
arg
aromatic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013500162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028543 external-priority patent/WO2011116007A1/en
Publication of JP2013522311A publication Critical patent/JP2013522311A/ja
Publication of JP2013522311A5 publication Critical patent/JP2013522311A5/ja
Pending legal-status Critical Current

Links

JP2013500162A 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法 Pending JP2013522311A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31394510P 2010-03-15 2010-03-15
US61/313,945 2010-03-15
US37681310P 2010-08-25 2010-08-25
US61/376,813 2010-08-25
PCT/US2011/028543 WO2011116007A1 (en) 2010-03-15 2011-03-15 Combination therapies using cyclosporine and aromatic cationic peptides

Publications (2)

Publication Number Publication Date
JP2013522311A JP2013522311A (ja) 2013-06-13
JP2013522311A5 true JP2013522311A5 (enExample) 2014-05-01

Family

ID=44649559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500162A Pending JP2013522311A (ja) 2010-03-15 2011-03-15 シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法

Country Status (4)

Country Link
US (4) US8697657B2 (enExample)
EP (6) EP3560508A1 (enExample)
JP (1) JP2013522311A (enExample)
WO (1) WO2011116007A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
EP3100739A1 (en) * 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN105879008A (zh) * 2010-07-09 2016-08-24 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
CN107496899A (zh) * 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3170506B1 (en) * 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
JP2014196281A (ja) * 2012-08-01 2014-10-16 健輔 江頭 医薬組成物
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
MX2015005102A (es) * 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
WO2014088631A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CN117752766A (zh) 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
CN115990242A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
CN105579054A (zh) * 2013-05-14 2016-05-11 康德生物医疗技术公司 预防或治疗左心室重塑的方法
US20140363391A1 (en) * 2013-06-06 2014-12-11 Demetris Yannopoulos System and method for administering poloxamers and anesthetics while performing cpr and minimizing reperfusion injury
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160175379A1 (en) * 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
CN112457368A (zh) * 2013-12-27 2021-03-09 康德生物医疗技术公司 药学相关的芳香族阳离子肽
CA2942143A1 (en) * 2014-03-03 2015-09-11 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides and methods of generating the same
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
US20170182117A1 (en) * 2014-05-28 2017-06-29 Stealth Biotherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
US10576124B2 (en) * 2014-05-28 2020-03-03 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EP3182989B1 (en) 2014-08-21 2021-04-14 Stealth Biotherapeutics Corp Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome
US10683534B2 (en) * 2015-01-27 2020-06-16 BioSpyder Technologies, Inc. Ligation assays in liquid phase
EP3256143A4 (en) * 2015-02-13 2018-11-21 Stealth Peptides International, Inc. Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
CA2978905A1 (en) * 2015-03-06 2016-09-15 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN109476700A (zh) * 2016-03-11 2019-03-15 隐形生物治疗公司 结晶盐形式
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
WO2018223032A1 (en) * 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
JP7606966B2 (ja) 2018-12-18 2024-12-26 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病を標的とするアナログ
KR20210093957A (ko) * 2018-12-18 2021-07-28 스텔스 바이오테라퓨틱스 코포레이션 미토콘드리아-표적화 펩타이드
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CA2971928C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
KR20070009674A (ko) * 2004-04-08 2007-01-18 노파르티스 아게 대뇌 허혈 및 뇌와 척수 상해에서의 ｎｉｍ８１１
WO2007129149A1 (en) * 2006-05-04 2007-11-15 Michel Ovize Use of cyclosporin a or melle4-cyclosporin for the treatment of acute myocardial infarction
EP2114427B1 (en) * 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2010076329A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
EP3100739A1 (en) 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
CN104725472A (zh) 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Similar Documents

Publication Publication Date Title
JP2013522311A5 (enExample)
CA2915005C (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
ES2398012T5 (es) Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
JP2009102342A5 (enExample)
JP2011500851A5 (enExample)
JP2011241213A5 (enExample)
JP2014515373A5 (enExample)
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
JP2013515739A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2023061943A (ja) ペプチド組成物
TW201601743A (zh) 外周ｋａｐｐａ鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途
JP2013518124A5 (enExample)
JP2008517991A5 (enExample)
JP2016505050A5 (enExample)
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
CA2582452A1 (en) Pegylated liposomal doxorubicin in combination with ecteinascidin 743
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
JP2020510043A5 (enExample)
TWI496579B (zh) 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途
ES2791301T3 (es) Combinación de canrenoato y exenatida
ES2671024T3 (es) Composición farmacéutica para administración transnasal
BR112019026336A2 (pt) forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico
CN114364691B (zh) 作为纤维化基质积累的抑制剂的肽
JP2014515751A5 (enExample)